屈大麻酚(Dronabinol) - 药物靶点：CB_在研适应症：厌食症，恶心，呕吐_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(-)-delta9-trans-Tetrahydrocannabinol、1-trans-delta-9-Tetrahydrocannabinol、3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol

+ [37]

靶点

CB

作用方式

激动剂

作用机制

CB激动剂(大麻素受体激动剂)

治疗领域

其他疾病神经系统疾病消化系统疾病+ [2]

在研适应症

非在研适应症

原研机构

在研机构

Tetra Bio-Pharma, Inc.

RespireRx Pharmaceuticals, Inc.

+ [3]

非在研机构

Unimed Pharmaceutical, Inc.Benuvia Therapeutics, Inc.

Solvay SA

权益机构

IntelGenx Corp.

Alkem Laboratories Ltd.

DanCann Pharma A/S

+ [6]

最高研发阶段批准上市

首次获批日期

美国 (1985-05-31),

厌食症恶心呕吐

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C21H30O2

InChIKeyCYQFCXCEBYINGO-IAGOWNOFSA-N

CAS号1972-08-3

关联

307

项与屈大麻酚相关的临床试验

NCT04855526

/ Not yet recruiting早期临床1期IIT

Effects of Marijuana on Memory-Related Neurochemistry and Neural Response

Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.

开始日期2025-12-01

申办/合作机构

Hartford Hospital

[+1]

NCT06956014

/ Not yet recruiting临床3期

Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of the Full-spectrum Cannabis Extract VER-01 in Patients With Chronic Low Back Pain

The aim of the trial is to prove the efficacy and safety of VER-01 corresponding to 22.5 mg or 32.5 mg THC compared to placebo in patients with chronic low back pain (CLBP) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

开始日期2025-11-01

申办/合作机构

Vertanical GmbH

NCT06731894

/ Not yet recruiting临床2期IIT

A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy

This phase II trials evaluates how well different types of phytocannabinoids (cannabidiol [CBD] versus tetrahydrocannabinol [THC] and CBD formulation [THC:CBD]) work to reduce chronic chemotherapy-induced peripheral neuropathy among breast and colon cancer survivors. Chemotherapy induced peripheral neuropathy is a set of symptoms that includes pain, tingling, numbness and motor weakness caused by certain types of chemotherapy treatment. Phytocannabinoids are compounds made by the cannabis plant, such as THC and CBD, that have been found to be an effective treatment for chronic pain. Phytocannabinoids may be effective in reducing chronic chemotherapy-induced peripheral neuropathy symptoms in patients treated for breast or colon cancer.

开始日期2025-10-27

申办/合作机构

City of Hope National Medical Center

[+1]

100 项与屈大麻酚相关的临床结果

登录后查看更多信息

100 项与屈大麻酚相关的转化医学

登录后查看更多信息

100 项与屈大麻酚相关的专利（医药）

登录后查看更多信息

15,747

项与屈大麻酚相关的文献（医药）

2025-12-31·Journal of Dermatological Treatment

The impact of cannabis use on local anesthetic dosing during hair restoration surgery: a case report, proposed mechanisms, and clinical recommendations

Review

作者: Keene, Sharon A. ; Gupta, Aditya K. ; Talukder, Mesbah

Cannabis use has increased significantly in the last decade. This article presents a case where a patient needed more local anesthetic (LA) than usual to induce effective anesthesia during hair transplant surgery. The reason cannabis users often need more LA is poorly understood. One possibility is that cannabis withdrawal effect makes patients more sensitive to pain and stress. Additionally, vasodilatory property of cannabis may speed up LA clearance from the application site. The interactions of two major cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC), with cannabinoid receptor type 1 (CB1), cannabinoid receptor type 2 (CB2), and transient receptor potential vanilloid 1 (TRPV1) receptors are also complex. Furthermore, CBD and THC function as cytochrome P450 enzyme inhibitors potentially impacting systemic metabolism. When planning to administer LA during hair restoration surgery in cannabis users, clinicians should obtain a detailed history of prior consumption (type of cannabis, frequency, dosage). Preoperative planning should consider the anticipated duration of surgery and calculate the maximum safe LA dose to avoid the risk of toxicity. Also, patients should be carefully monitored for vital signs during surgery. If a patient requires frequent re-injection to remain pain free, the surgeon may need to re-assess the surgical plan to avoid toxicity.

2025-09-01·Journal of Pharmaceutical and Biomedical Analysis

HPLC method for novel cannabinoid separation with electrochemical detection on boron-doped diamond electrode

Article

作者: Hrbac, Jan ; Petr, Jan ; Jirovsky, David ; Belbasi, Zeynab

In this study, we developed a novel and environmentally friendly method for the determination of selected cannabinoids - cannabidiol, cannabinol, tetrahydrocannabinol, JWH 073 synthetic cannabinoid, hexahydrocannabinol (HHC), and hexahydrocannabinol-O-acetate - using high-performance liquid chromatography with electrochemical detection. The method employs a boron-doped diamond working electrode, which offers significant advantages in comparison with commonly used materials. Its main strengths include low background currents, reduced fouling, and an extended potential window, making it suitable for detecting compounds that are not readily oxidizable. The chromatographic system utilized a reversed-phase Gemini C18 column with a mobile phase consisting of acetonitrile and 25 mM phosphate buffer (pH 4.4) in step-gradient mode from 68 % to 88 % acetonitrile. The separation and determination of cannabinoids were optimized to be completed in less than 25 min. Hydrodynamic voltammetry was performed to identify the optimal potential for the amperometric detection, with a working potential of + 1400 mV (vs. Pd/H₂) providing the best analytical response based on S/N ratio. Under these optimal separation and detection conditions, the limits of detection were within the range of 6.1-666 nM (for cannabidiol and 9(R)-hexahydrocannabinol-O-acetate), while the response was linear within the concentration range measured up to 10 μM. The method demonstrated good linearity, precision, and sensitivity, with limits of detection and quantitation reaching nanomolar levels. The developed method was successfully applied to commercial samples of HHC jelly bears and HHC distillate.

2025-08-01·Addictive Behaviors

Exposure to vaping and smoking prohibitions and nicotine and cannabis vaping in a California-based sample of young adults: An ecological momentary assessment study

Article

作者: Dunbar, Michael S ; Rodriguez, Anthony ; Tucker, Joan S ; Seelam, Rachana ; Setodji, Claude M ; D'Amico, Elizabeth J

BACKGROUNDLocalities have extended smoke-free policies to prohibit use of combustible and vaping products for nicotine/tobacco and cannabis (THC), but little is known about how this affects vaping behavior. We used Ecological Momentary Assessment to examine perceived exposure to smoking- and vaping-specific prohibitions and nicotine and THC vaping.METHODSYoung adults (n = 178; age 25; 55 % male; 47 % Hispanic, 21 % Asian, 21 % White) in California who endorsed past-month use of nicotine and/or THC vaping products were recruited from an existing longitudinal study. In 2023, individuals completed up to five brief surveys each day over 21 days to assess vaping behavior and momentary context (e.g., vaping/smoking prohibitions) of vaping and non-use (random prompt) events. Multilevel generalized linear mixed models assessed associations between exposure to prohibitions and likelihood of vaping nicotine or THC (vs. non-use events).RESULTSYoung adults showed reduced likelihood of vaping nicotine (aOR = 0.60, 95 % CI 0.42 - 0.85; p = 0.004) and THC (aOR = 0.48, 95 % CI 0.33 - 0.69; p < 0.0001) in settings where vaping and smoking were prohibited compared to settings in which vaping and smoking were allowed. Exposure to settings in which only smoking was prohibited (vaping allowed) was associated with increased likelihood of vaping nicotine (aOR = 2.13, 95 % CI 1.34 - 3.39; p = 0.002), but unrelated to vaping THC (aOR = 0.87, 95 % CI 0.53 - 1.44; p = 0.59).CONCLUSIONSEfforts to increase young people's awareness of and compliance with vaping prohibitions may help reduce both nicotine and THC vaping in real-world settings.

512

项与屈大麻酚相关的新闻（医药）

2025-04-25

·GlobeNewswire-Health Care

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. The patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc’s Palmitoylethanolamide (“PEA”). This innovative combination aims to address the complex neurobiological and psychological factors associated with eating disorders, offering a potential new avenue for treatment. Eating disorders are serious mental health conditions that negatively impact an individual’s health, emotions, and ability to perform daily functions. Eating disorders are among the top ten leading causes of disability among young women and have one of the highest mortality rates compared to other mental disorders. According to recent studies, up to 70 million people globally are affected by eating disorders, with significant increases observed among children and adolescents. Global eating disorder prevalence increased from 3.4% to 7.8% between 2000 and 2018. About SciSparc Ltd. (Nasdaq: SPRC): SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on Amazon Marketplace. About Clearmind Medicine Inc. (“Clearmind”) Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Clearmind’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. Clearmind intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Common shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.” For further information visit: https://www.clearmindmedicine.com Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses the potential of its proprietary treatment to treat anorexia, bulimia and other eating disorders. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@scisparc.comTel: +972-3-6167055

2025-04-17

·CPHI制药在线

中药新药大爆发，宝仁堂药业进军“鼾症”市场

关注并星标CPHI制药在线4月9日，CDE官网显示，宝仁堂药业自主研发的1.1类创新中药“三贝苎鼾胶囊”的上市申请获受理。三贝苎鼾胶囊是宝仁堂药业依据祖传治疗“鼾症”的配方进行自主研发的中药，用于治疗阻塞性睡眠呼吸暂停（OSA）。2024年12月，该药治疗阻塞性睡眠呼吸暂停低通气综合征（痰瘀互结证）的多中心、随机、双盲、安慰剂平行对照3期临床试验总结会成功召开。结果显示：三贝苎鼾胶囊治疗OSA疗效显著，可明显降低呼吸暂停低通气指数（AHI），提高应答率，且药物安全性良好。OSA指患者在睡眠过程中反复出现呼吸暂停和低通气，临床表现为打鼾，鼾声大且不规律，夜间窒息感或憋醒，睡眠紊乱，白天出现嗜睡，记忆力下降，严重者出现认知功能下降，行为异常。据美国睡眠医学会估计，2025年全球OSA患病人数将增加到11.6亿。我国的OSA患者人数居全球首位，其次是美国、巴西和印度。目前，OSA的治疗手段主要包括危险因素控制（如饮食控制、加强锻炼）、体位治疗（无创气道正压通气治疗）、口腔矫治和外科手术治疗。2024年12月，FDA批准首款OSA直接治疗药物Zepbound（tirzepatide）。该药是全球首款获批上市的GLP-1/GIP双重受体激动剂，被FDA批准用于治疗中重度OSA合并肥胖症成人患者，且还被批准用于降糖和减重。此外，目前全球还有多款在研OSA新药，如AD109（Apnimed，3期临床）、IHL-42X（Incannex，2/3期临床）、THX-110（SciSparc，2期临床）、BIOS-0618（百诚医药，获批临床）。AD109是一种包含具选择性的去甲肾上腺素再摄取抑制剂托莫西汀与抗毒蕈碱aroxybutynin的组合配方，通过靶向OSA关键的神经通路，活化上呼吸道扩张肌，使得患者在睡眠时仍可维持呼吸道的畅通。AD109治疗OSA的2b期临床试验MARIPOSA结果显示：与安慰剂相比，AD109组患者的呼吸暂停低通气指数（AHI4，呼吸不足定义为4%饱和度降低）降低45%，达到主要研究终点。而且，2.5/75 mg AD109组患者在PROMIS疲劳量表（该量表测量日间疲劳程度及OSA对日常活动的影响）上表现出统计学显著改善。AD109使用方便，每天仅需睡前口服一次，曾被FDA授予快速通道资格。IHL-42X是屈大麻酚和乙酰唑胺的组合，已完成2期概念验证临床试验结果显示：与基线相比，使用低剂量 IHL-42X，患者AHI减少50.7%。此外，IHL-42X还能够改善患者的睡眠质量。THX-110是基于大麻素的创新药物之一，由屈大麻酚和大麻素棕榈酰乙醇酰胺组合而成。人的大脑和免疫系统中存在有大麻素受体，THX-110旨在刺激中枢神经系统的大麻素受体，抑制内源性大麻素的代谢降解，提高四氢大麻酚的吸收。中药新药大爆发2025第一季度批准8款在国家大力发展中医药创新的背景下，我国中药市场持续向好，中药创新也进一步加速。据悉2024年NMPA共批准12个中药新药，其中包括3个1.1类中药复方制剂（即儿茶上清丸、九味止咳口服液和秦威颗粒），8个3.1类按古代经典名方目录管理的中药复方制剂（即芍药甘草颗粒、苓桂术甘颗粒、温经汤颗粒、当归补血汤颗粒、二冬汤颗粒、一贯煎颗粒、枇杷清肺颗粒）和1个3.2类其他来源于古代经典名方的中药复方制剂（即温阳解毒颗粒）。2025年中药新药获批数量有望再攀新高。据悉，2025年第一季度NMPA已批准8款中药新药（详见下表），其中包括2款1.1类中药复方制剂。此外，截至2025年4月10日，据CDE官网，已有17款中药新药申请上市（详见下图），其中包括4款1.1类新药，即宝仁堂药业的三贝苎鼾胶囊（治疗阻塞性睡眠呼吸暂停）、以岭药业的芪桂络痹通片（治疗类风湿关节炎）、康缘药业的六味地黄苷糖片（治疗更年期综合征）和天士力的安神滴丸（治疗失眠症）。仅从2025年第一季度批准以及报产的中药新药来看，我国中药新药进入收获期，且覆盖的适应症愈发广泛。期待在利好政策的加持下，我国中药新药在人类抗击疾病的历史上更佳灿烂辉煌。END2025金笔奖征文即将截止，速来投稿！领取CPHI & PMEC China 2025展会门票智药研习社课程预告来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

快速通道临床3期临床2期临床结果上市批准

2025-04-16

·GlobeNewswire-Health Care

Avicanna Announces Revocation of Management Cease Trade Order

TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce the Management Cease Trade Order (“MCTO”) issued on April 4, 2025 by the Ontario Securities Commission (“OSC”) has now been revoked. As previously announced, all required filings have been filed by the Company. Following the filing of required filings, the OSC has revoked the MCTO. Copies of the required filings are available on the Company’s SEDAR+ profile at www.sedarplus.ca. About Avicanna: Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars. Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders.Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally. SOURCE Avicanna Inc. Stay Connected For more information about Avicanna, visit our website or contact Ivana Maric by email at info@avicanna.com. Cautionary Note Regarding Forward-Looking Information and Statements This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Offering, the use of proceeds of the Offering, the receipt of all approvals of the Toronto Stock Exchange in connection with the Offering, statements with respect to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 11, 2025, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

100 项与屈大麻酚相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00306	屈大麻酚	A04AD10	DB00470

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
厌食症	美国	Alkem Laboratories Ltd.	1985-05-31
恶心	美国	Alkem Laboratories Ltd.	1985-05-31
呕吐	美国	Alkem Laboratories Ltd.	1985-05-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
化疗引起的恶心和呕吐	申请上市	加拿大	Tetra Bio-Pharma, Inc.	2023-05-01
阻塞性睡眠呼吸暂停综合征	临床3期	美国	RespireRx Pharmaceuticals, Inc.	2023-02-01
食欲减退	临床1期	欧洲	Solvay SA	2007-02-15
阿尔茨海默症	临床1期	美国	Unimed Pharmaceutical, Inc.	1996-07-29
抑郁症	临床1期	美国	Unimed Pharmaceutical, Inc.	1996-07-29
帕金森病	临床前	加拿大	Pike Therapeutics, Inc.	2024-11-01
认知障碍	临床前	以色列	Therapix Biosciences Ltd /Non-Pain Assets/	2018-05-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03804840 (AIS, CTgov)	早期临床1期	1型血小板减少症	72	Placebo (Placebo)	顧願遞齋壓膚獵艱鬱繭(廠築鑰膚願觸壓範鏇築) = 艱製觸網衊襯鹽願壓餘鏇壓鹽製獵築憲網選鑰 (膚鏇觸膚糧蓋醖遞製繭, 選遞繭齋窪繭憲餘餘築 ~ 鬱簾窪鹽鹹醖艱範窪積) 更多	-	2024-09-19
				Dronabinol (7.5 mg THC)	顧願遞齋壓膚獵艱鬱繭(廠築鑰膚願觸壓範鏇築) = 鹽夢餘窪觸鬱顧願積醖鏇壓鹽製獵築憲網選鑰 (膚鏇觸膚糧蓋醖遞製繭, 鹹鏇築窪鬱觸鬱憲夢範 ~ 鑰積糧夢構糧觸網製壓) 更多
NCT03809546 (IDT, CTgov)	早期临床1期	1型血小板减少症	60	dextrose (Placebo)	壓範鬱繭艱繭齋夢糧壓(憲積獵築餘壓襯衊廠糧) = 憲蓋積鏇鹹醖糧淵遞糧餘醖齋繭糧醖鏇壓選襯 (鏇遞鑰壓壓遞廠觸糧糧, 鹽築憲繭壓蓋醖鏇積鹹 ~ 醖選鏇廠夢築鑰網膚繭) 更多	-	2024-07-03
				Dronabinol (7.5 mg THC)	壓範鬱繭艱繭齋夢糧壓(憲積獵築餘壓襯衊廠糧) = 壓餘餘獵繭簾艱淵築範餘醖齋繭糧醖鏇壓選襯 (鏇遞鑰壓壓遞廠觸糧糧, 觸憲構餘範膚膚範膚衊 ~ 淵糧餘淵蓋壓繭鑰顧積) 更多
NCT05192239 (CTgov)	早期临床1期	-	17	Placebo (Placebo)	淵範膚築築艱獵鬱構獵(蓋遞窪製繭淵鹽衊齋鹹) = 觸網齋廠獵齋簾遞夢醖網窪壓鹹衊醖獵鏇窪簾 (艱襯窪願鑰窪餘獵鹹鬱, 積衊淵窪繭願艱選蓋壓 ~ 窪窪餘簾糧遞齋壓簾壓) 更多	-	2024-04-22
				THC 5 (10 mg THC)	淵範膚築築艱獵鬱構獵(蓋遞窪製繭淵鹽衊齋鹹) = 願簾選鑰鹽願蓋鬱製遞網窪壓鹹衊醖獵鏇窪簾 (艱襯窪願鑰窪餘獵鹹鬱, 繭衊蓋憲憲艱願廠鹹膚 ~ 膚願鬱膚壓膚製製廠選) 更多
NCT04294966 (ART, CTgov)	早期临床1期	-	24	Dextrose (Placebo)	網積鏇艱網蓋築遞壓鹹(築艱築簾選簾鹽繭襯夢) = 構窪艱願願夢遞壓艱製醖遞淵繭艱夢築醖艱遞 (餘蓋蓋鏇範簾鹽醖積鬱, 願願遞壓構廠遞鹽艱廠 ~ 鏇鹽壓繭獵範鏇廠壓範) 更多	-	2023-11-09
				Dronabinol (7.5 mg THC)	網積鏇艱網蓋築遞壓鹹(築艱築簾選簾鹽繭襯夢) = 簾夢選構艱衊構鏇積築醖遞淵繭艱夢築醖艱遞 (餘蓋蓋鏇範簾鹽醖積鬱, 廠衊夢餘製繭願構鏇顧 ~ 鬱鑰繭齋顧製選齋齋築) 更多
NCT03609853 (CTgov)	临床1期	-	53	Placebo (Placebo)	糧願蓋襯顧餘獵鑰衊窪(糧鬱蓋遞窪顧範製衊鏇) = 製憲膚艱願窪獵網廠齋蓋鬱遞構廠鑰夢淵構觸 (鹽餘構構築鑰顧衊壓糧, 獵選鏇觸齋壓鹽衊齋簾 ~ 糧鏇廠願衊鹹糧夢艱廠) 更多	-	2023-10-18
				limonene+THC (Vaporized Low THC)	糧願蓋襯顧餘獵鑰衊窪(糧鬱蓋遞窪顧範製衊鏇) = 膚廠顧廠築製廠糧鬱醖蓋鬱遞構廠鑰夢淵構觸 (鹽餘構構築鑰顧衊壓糧, 襯築糧構襯範糧壓壓淵 ~ 遞淵艱襯壓憲憲構鏇糧) 更多
NCT02460692 (CTgov)	临床2期	腰痛 \| 神经痛	131	Placebos (Placebos)	鹽繭鏇鑰廠淵繭壓鏇製(鹹蓋鹽積獵齋觸鹽膚鹹) = 遞壓壓獵製願顧鏇糧蓋淵鹹積網夢鬱選選願襯 (願蓋淵繭膚廠鬱鹽選襯, 觸鏇艱範艱鏇顧壓齋廠 ~ 築鬱網壓選壓築鹽蓋糧) 更多	-	2023-09-28
				Dronabinol (Dronabinol)	鹽繭鏇鑰廠淵繭壓鏇製(鹹蓋鹽積獵齋觸鹽膚鹹) = 襯繭鬱繭衊壓繭簾憲艱淵鹹積網夢鬱選選願襯 (願蓋淵繭膚廠鬱鹽選襯, 廠艱範築餘糧顧膚糧廠 ~ 觸顧壓艱壓構願構襯鏇) 更多
NCT04201197 (CTgov)	临床1期	药物相互作用	22	Inje cocktail (Inje Cocktail)	艱壓鹽廠構窪醖簾鬱獵(獵憲鑰網膚廠鹽廠築繭) = 築齋鏇窪積獵顧淵齋淵夢築顧憲膚糧築鬱淵築 (選繭選糧遞獵艱鹽鏇醖, 繭積醖顧鹹窪衊鏇遞觸 ~ 艱獵廠鹽選糧餘鬱範繭) 更多	-	2023-07-24
				Inje cocktail+THC Cannabis extract (Inje Cocktail + THC Extract)	艱壓鹽廠構窪醖簾鬱獵(獵憲鑰網膚廠鹽廠築繭) = 獵艱襯鹹襯鬱淵遞齋蓋夢築顧憲膚糧築鬱淵築 (選繭選糧遞獵艱鹽鏇醖, 選壓齋獵製憲繭選繭糧 ~ 簾醖範憲遞衊膚製齋膚) 更多
EAN2023	N/A	神经痛	114	Placebo	(範獵觸鏇築壓鹽鏇顧窪) = 廠醖淵襯選鬱鹹憲淵壓衊衊鏇構獵選壓觸網鑰 (選鏇鏇膚鹹衊製觸衊鹹, 1.17 ~ 2.43)	不佳	2023-06-28
				THC	(範獵觸鏇築壓鹽鏇顧窪) = 鑰夢壓觸衊製憲餘糧壓衊衊鏇構獵選壓觸網鑰 (選鏇鏇膚鹹衊製觸衊鹹, 0.53 ~ 2.24)
AACR2023	N/A	肿瘤	343	Δ9-tetrahydrocannabinol (THC) (Cancer patients and survivors who consumed cannabis since diagnosis)	糧繭鏇遞淵糧夢遞製衊(窪餘範願窪廠範簾膚獵) = 簾顧簾製鹽膚製齋製鏇夢範鹽廠範觸餘艱夢願 (顧範鹹醖餘製鹽鬱壓壓 )	-	2023-04-04
EP401/#975 (IGCS2022)	N/A	化疗引起的恶心和呕吐	74	THC cannabis oil	(窪壓齋網餘製獵獵餘餘) = 簾獵簾壓醖鹹襯選顧繭鏇糧遞願憲鹹壓製餘糧 (鑰鬱衊繭範鹹觸鹽觸襯 )	不佳	2022-12-04
				Placebo	(窪壓齋網餘製獵獵餘餘) = 繭觸鑰夢餘繭壓壓積鬱鏇糧遞願憲鹹壓製餘糧 (鑰鬱衊繭範鹹觸鹽觸襯 )